Appetite suppressants and valvular heart disease

American Journal of the Medical Sciences

Volumn 321, Issue 4, 2001, Pages 285-291

  Weissman, Neil J ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Diet; Echocardiography; Heart valve disease; Obesity; Regurgitation

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE;

AORTA VALVE REGURGITATION; APPETITE; CLINICAL TRIAL; CONFERENCE PAPER; DIET; DISEASE SEVERITY; DOSE RESPONSE; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; ECHOCARDIOGRAPHY; FOOD AND DRUG ADMINISTRATION; HEART VALVE REGURGITATION; HEART VALVE REPLACEMENT; HUMAN; MITRAL VALVE REGURGITATION; OBESITY; PREVALENCE; VALVULAR HEART DISEASE;

EID: 0035060595     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200104000-00008     Document Type: Conference Paper

References (24)

1. Prepublication release of Journal articles
2. Valvular heart disease associated with fenfluramine-phentermine [published erratum appears in N Engl J Med 1997;337:1783]
3. Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota
4. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine U.S. Department of Health and Human Services interim public health recommendations, November 1997
5. Prevalence of valvular regurgitation in a population based cohort
6. Age-related prevalence of valvular regurgitation in normal subjects: A comprehensive color flow examination of 118 volunteers
7. Obesity and valvular regurgitation: Is there an association [abstract]?
8. Echocardiography in serial evaluation of left ventricular systolic and diastolic function: Importance of image acquisition, quantitation, and physiologic variability in clinical and investigational applications
9. Color Doppler assessment of mitral regurgitation with orthogonal planes
10. Evaluation of aortic insufficiency by Doppler color flow mapping
11. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
12. Low prevalence of valvular disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months
13. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs
14. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group
15. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication
16. Fenfluramine and phentermine and cardiovascular findings: Effect of treatment duration on prevalence of valve abnormalities
17. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine
18. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine
19. Dose and duration of appetite suppressant therapy impacts incidence of valvular heart disease
20. Hormonal responses to fenfluramine in depressed and control subjects
21. Phentermine and other monoamine-oxidase inhibitors may increase plasma serotonin when given with fenfluramines
22. Effects of fenfluramine and phentermine (fen-phen) on dopamine and serotonin release in rat striatum: In vivo microdialysis study in conscious animals
23. Natural history of valvular regurgitation one year after discontinuation of dexfenfluramine
24. Guidelines for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on Management of Patients with Valvular Heart Disease)